Population Pharmacokinetics and Evaluation dosing of Ceftolozane-Tazobactam in Critically ill Patients

Population Pharmacokinetics and Evaluation dosing of Ceftolozane-Tazobactam in Critically ill Patients - Population Pharmacokinetics and Evaluation dosing of Ceftolozane-Tazobactam in Critically ill Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043201

Enrollment

Registered

2021-02-01

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney disease due to sepsis

Interventions

Sampling of patient blood and sulfate of continuous renal r eplacement therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Inpatients administered ceftolozan-tazobactam in the ICU 2) Patients over 20 years old 3) Patients whose written consent has been obtained by the patient or his / her substitute

Exclusion criteria

Exclusion criteria: 1) Patients with a history of anaphylaxis-like symptoms due to ceftolozan tazobactam 2) Patients diagnosed as pregnant at the time of consent 3) Patients who participate in or participate in other evaluations

Design outcomes

Primary

Measure	Time frame
Comparison of ceftolozan-tazobactam pharmacokinetics by renal function	—

Countries

Japan

Contacts

Public ContactTakeshi Ide

Hyogo College of Medicine Intensive Care Unit

tide7977@gmail.com0798-45-6389

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026